Insider · CIK 0002038798
Sheldon Sloan
Files at SYRE (Spyre Therapeutics, Inc.). First filing Apr 3, 2026, latest Jul 2, 2026.
In brief
Sheldon Sloan files SEC Form 4 as officer at SYRE (Spyre Therapeutics, Inc.). Since Apr 3, 2026, Sheldon Sloan has reported 0 open-market buys worth $0 and 4 open-market sells worth $7.4M, the latest filed on Jul 2, 2026.
A track record needs three past buys with six months of prices behind them; Sheldon Sloan has 0, so none is measured yet.
The newest scored trade: sold $731k of SYRE on Jul 1, 2026, filed Jul 2, 2026, scored 36 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 4 sells worth $7.4M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SYRE: Spyre Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Spyre Therapeutics, Inc. | $731k 8,334 shares | -100% | +500% from low-11% from high | |
| 35Weak | Spyre Therapeutics, Inc. | $625k 8,333 shares | -100% | +401% from low-4% from high | |
| 40Moderate | Spyre Therapeutics, Inc. | $5.6M 78,333 shares | -100% | +455% from low-7% from high | |
| 31Weak | Spyre Therapeutics, Inc. | $398k 7,958 shares | -100% | +314% from low-3% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 3, 2026 | SYRE SPYRE THERAPEUTICS INC | 16,667 0.02% of outstanding | $1.2M | Jun 3, 2026 | $6.0M |
| May 1, 2026 | SYRE SPYRE THERAPEUTICS, INC. | 78,333 0.10% of outstanding | $5.8M | May 1, 2026 | $398k |
| Apr 1, 2026 | SYRE SPYRE THERAPEUTICS INC | 7,958 0.01% of outstanding | $401k | Apr 1, 2026 | none |
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | SYRE Spyre Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +8,334 | $27.46 | $229k | 8,334 | Jul 2, 2026 |
| Jul 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -6,500 | $87.52 | $569k | 1,834 | Jul 2, 2026 |
| Jul 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,834 | $88.34 | $162k | 0 | Jul 2, 2026 |
| Jul 1, 2026 | SYRE Spyre Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,334 | $0.00 | $0 | 305,000 | Jul 2, 2026 |
| Jun 3, 2026 | SYRE Spyre Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +8,333 | $27.46 | $229k | 8,333 | Jun 3, 2026 |
| Jun 3, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,333 | $75.00 | $625k | 0 | Jun 3, 2026 |
| Jun 3, 2026 | SYRE Spyre Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,333 | $0.00 | $0 | 313,334 | Jun 3, 2026 |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +78,333 | $27.46 | $2.2M | 78,333 | May 1, 2026 |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -21,306 | $69.53 | $1.5M | 57,027 | May 1, 2026 |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -19,656 | $70.61 | $1.4M | 37,371 | May 1, 2026 |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,777 | $71.56 | $628k | 28,594 | May 1, 2026 |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -12,777 | $72.94 | $932k | 15,817 | May 1, 2026 |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -10,358 | $73.74 | $764k | 5,459 | May 1, 2026 |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -5,059 | $74.60 | $377k | 400 | May 1, 2026 |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -400 | $75.37 | $30k | 0 | May 1, 2026 |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -78,333 | $0.00 | $0 | 321,667 | May 1, 2026 |
| Apr 1, 2026 | SYRE Spyre Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +7,958 | $21.66 | $172k | 7,958 | Apr 3, 2026 |
| Apr 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -7,958 | $50.00 | $398k | 0 | Apr 3, 2026 |
| Apr 1, 2026 | SYRE Spyre Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,958 | $0.00 | $0 | 87,542 | Apr 3, 2026 |
| Jan 9, 2026 | SYRE Spyre Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +140,000 | $0.00 | $0 | 140,000 | Jan 13, 2026 |
Questions about Sheldon Sloan
Answered from the filings on this page, as of the latest one.
Is Sheldon Sloan buying or selling?
In the last 12 months Sheldon Sloan reported 0 open-market buys worth $0 and 4 open-market sells worth $7.4M on SEC Form 4; the latest was sold $731k of SYRE on Jul 1, 2026. Grants, option exercises and tax withholding are not counted.
How did Sheldon Sloan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sheldon Sloan has 0.
Where does Sheldon Sloan file Form 4?
Sheldon Sloan has filed Form 4 at SYRE (Spyre Therapeutics, Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.